Inflammation-related pathways and cytokine networks

Inflammation-related pathways and cytokine networks represent a complex, integrated system of signaling molecules and cellular processes that coordinate the body's response to harmful stimuli (Source: NIH, Inflammation). This designation is typically used in drug development to describe a broad therapeutic focus rather than a single, discrete molecular target like a specific receptor or enzyme (Source: Nature Reviews Drug Discovery, PMID: 12728250). These networks involve a variety of cytokines—including Tumor Necrosis Factor (TNF), Interleukins (IL-1, IL-6, IL-17), and Interferons—as well as intracellular signaling hubs like NF-κB and the JAK-STAT pathway (Source: PubMed, PMID: 28138231). Dysregulation of these pathways is a hallmark of numerous chronic conditions, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Drugs categorized under this heading, such as mesalamine or certain immunomodulators, often exert pleiotropic effects that dampen the overall inflammatory environment rather than blocking a single pathway (Source: StatPearls, Anti-inflammatory Medications). While effective, the broad nature of these networks means that therapeutic intervention can lead to significant safety concerns, primarily related to systemic immunosuppression and an increased risk of opportunistic infections.

Other names

Inflammatory cascadeCytokine networkInflammatory signaling pathwaysMultiple inflammation-related pathways

Pleiotropic modulation of multiple inflammatory signaling cascades, including the inhibition of pro-inflammatory cytokine production and the suppression of nuclear factor-kappa B (NF-κB) activation.